BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16518475)

  • 1. [Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin].
    Lehoczky O; Pulay T
    Magy Onkol; 2005; 49(4):315-8. PubMed ID: 16518475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma].
    Lehoczky O; Pulay T
    Orv Hetil; 2003 Jul; 144(28):1381-4. PubMed ID: 12914122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
    Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
    Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
    J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
    Dinniwell R; Lock M; Pintilie M; Fyles A; Laframboise S; Depetrillo D; Levin W; Manchul L; Murphy J; Oza A; Rosen B; Sturgeon J; Milosevic M
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):104-10. PubMed ID: 15850909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.
    Young RC
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):8-10. PubMed ID: 10952120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinosarcoma of the ovary-a case series.
    Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
    Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Kalman L; Castine M; Sylvester L; Greco FA
    Gynecol Oncol; 2005 Apr; 97(1):200-5. PubMed ID: 15790459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.